-$0.72 Earnings Per Share Expected for OptiNose Inc (OPTN) This Quarter

Equities analysts predict that OptiNose Inc (NASDAQ:OPTN) will report earnings of ($0.72) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for OptiNose’s earnings, with the lowest EPS estimate coming in at ($0.75) and the highest estimate coming in at ($0.69). OptiNose reported earnings per share of ($0.64) during the same quarter last year, which suggests a negative year over year growth rate of 12.5%. The firm is expected to announce its next earnings results on Tuesday, August 13th.

On average, analysts expect that OptiNose will report full-year earnings of ($2.91) per share for the current fiscal year, with EPS estimates ranging from ($2.98) to ($2.80). For the next year, analysts anticipate that the firm will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.77). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover OptiNose.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.01. OptiNose had a negative return on equity of 81.04% and a negative net margin of 983.22%. The business had revenue of $4.48 million for the quarter, compared to analyst estimates of $4.35 million.

Several brokerages have commented on OPTN. Zacks Investment Research downgraded shares of OptiNose from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Cantor Fitzgerald restated a “buy” rating and set a $27.00 price objective on shares of OptiNose in a research report on Thursday, May 9th. Royal Bank of Canada lowered their price objective on shares of OptiNose to $25.00 and set an “outperform” rating on the stock in a research report on Thursday, March 7th. Finally, Piper Jaffray Companies set a $29.00 price objective on shares of OptiNose and gave the company a “buy” rating in a research report on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. OptiNose currently has a consensus rating of “Buy” and an average target price of $27.80.

Shares of OPTN stock traded down $0.22 during trading hours on Thursday, hitting $6.93. 5,813 shares of the company were exchanged, compared to its average volume of 157,399. The company has a quick ratio of 6.74, a current ratio of 6.95 and a debt-to-equity ratio of 0.79. OptiNose has a 52-week low of $5.66 and a 52-week high of $30.00. The firm has a market cap of $304.53 million, a P/E ratio of -2.59 and a beta of 1.09.

A number of large investors have recently modified their holdings of OPTN. BNP Paribas Arbitrage SA lifted its stake in shares of OptiNose by 1,569.2% in the first quarter. BNP Paribas Arbitrage SA now owns 4,006 shares of the company’s stock worth $41,000 after buying an additional 3,766 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of OptiNose in the 4th quarter valued at about $45,000. Citigroup Inc. lifted its stake in shares of OptiNose by 37.3% in the 1st quarter. Citigroup Inc. now owns 5,840 shares of the company’s stock valued at $60,000 after purchasing an additional 1,588 shares in the last quarter. Stifel Financial Corp acquired a new position in shares of OptiNose in the 4th quarter valued at about $63,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of OptiNose during the 4th quarter valued at about $135,000. Institutional investors own 63.68% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.